No Data
Morgan Stanley Initiates Apellis Pharmaceuticals(APLS.US) With Hold Rating, Announces Target Price $31
Neutral Stance on Apellis Pharmaceuticals Amid Competitive Uncertainties and Market Stability
Scotiabank Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Maintains Target Price $30
Apellis Pharmaceuticals Up Nearly 16%, On Pace for Largest Percent Increase Since August 2023 -- Data Talk
Energizer, C3.ai, Insmed And Other Big Stocks Moving Higher On Tuesday
Astellas Receives Complete Response Letter From FDA for Izervay SNDA
No Data
No Data
